TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17387026

Group type: EXPERIMENTAL
Intervention: Aceclofenac 100 mg twice daily
Number of subjects: 168

Group type: COMPARATOR
Intervention: Paracetamol 1000 mg three times daily
Number of subjects: 168
Study: 15596757

Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg/day
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Pregabalin 600 mg/day
Number of subjects: 338

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Pregabalin (300 mg/day and 600 mg/day)
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 338
Study: 11501247

Group type: EXPERIMENTAL
Intervention: Incredible Years program (experimental condition)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Regular Head Start program (control condition)
Number of subjects: 272
Study: 9404176

Group type: EXPERIMENTAL
Intervention: nalbuphine 0.1 mg.kg‐1
Number of subjects: 90

Group type: COMPARATOR
Intervention: pethidine 1 mg.kg‐1
Number of subjects: 90
Study: 8424396

Group type: COMPARATOR
Intervention: Mitomycin (M)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Mitomycin plus high-dose medroxyprogesterone acetate (MMPA)
Number of subjects: 76
Study: 2462473

Group type: EXPERIMENTAL
Intervention: Cadexomer iodine (CI)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Dextranomer
Number of subjects: 42
Study: 31257067

Group type: EXPERIMENTAL
Intervention: Tailored therapy (PPI, amoxicillin, and clarithromycin for 7 days; PPI, amoxicillin, and levofloxacin for 10 days; PPI, amoxicillin, and metronidazole for 14 days)
Number of subjects: 526

Group type: COMPARATOR
Intervention: Empirical therapy (PPI, amoxicillin, and clarithromycin for 7 days)
Number of subjects: 526
Study: 28762476

Group type: EXPERIMENTAL
Intervention: Upadacitinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Food effect
Number of subjects: 0

Group type: COMPARATOR
Intervention: Manual ECG adjudication
Number of subjects: 0
Study: 26509763

Group type: EXPERIMENTAL
Intervention: Gatifloxacin 0.3% (monotherapy)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Fortified cefazolin sodium 5% and tobramycin sulfate 1.3% (combination therapy)
Number of subjects: 204
Study: 25327732

Group type: EXPERIMENTAL
Intervention: YAZ (drospirenone 3 mg and ethinylestradiol 20 µg)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: YAZ
Number of subjects: 187
Study: 23752209

Group type: EXPERIMENTAL
Intervention: Pentax AirWay Scope (AWS)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 46
Study: 21038654

Group type: EXPERIMENTAL
Intervention: Shenyanning (SYN) Decoction, one dose per day for 1 year
Number of subjects: 70

Group type: COMPARATOR
Intervention: Losartan (50 mg per day for 1 year)
Number of subjects: 70
Study: 18539767

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 27
Study: 16158780

Group type: COMPARATOR
Intervention: Hydroxicine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Montelukast plus desloratadine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Desloratadine
Number of subjects: 40
Study: 12940665

Group type: EXPERIMENTAL
Intervention: Submucosal resection
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Submucosal resection with lateral displacement
Number of subjects: 382

Group type: COMPARATOR
Intervention: Turbinectomy
Number of subjects: 382

Group type: COMPARATOR
Intervention: Laser cautery
Number of subjects: 382

Group type: COMPARATOR
Intervention: Electrocautery
Number of subjects: 382

Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 382
Study: 12799884

Group type: EXPERIMENTAL
Intervention: Laparoscopy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 40
Study: 10407236

Group type: EXPERIMENTAL
Intervention: Changes in intake of various dietary lipids
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Hierarchical model for meta-analysis
Number of subjects: 71
Study: 8565023

Group type: EXPERIMENTAL
Intervention: Naproxen sodium (NAP)
Number of subjects: 4138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4138

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 4138

Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 4138
Study: 2646418

Group type: EXPERIMENTAL
Intervention: 7% tetrapotassium peroxydiphosphate (PDP) solution administered as a subgingival irrigant
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo rinse similar to the test solution, but without PDP
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 7% tetrapotassium peroxydiphosphate (PDP) solution
Number of subjects: 40
Study: 913873

Group type: EXPERIMENTAL
Intervention: Phenylbutazone 50 mg/day
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Phenylbutazone 100 mg/day
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Phenylbutazone 200 mg/day
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Phenylbutazone 400 mg/day
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Phenylbutazone (all doses)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Phenylbutazone 50 and 100 mg/day
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Phenylbutazone 200 and 400 mg/day
Number of subjects: 7
Study: 31704518

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS) over the left inferior frontal gyrus combined with written naming/spelling therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham tDCS over the left inferior frontal gyrus combined with written naming/spelling therapy
Number of subjects: 30
Study: 27876449

Group type: EXPERIMENTAL
Intervention: Paraffin therapy (n = 27)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo therapy (n = 25)
Number of subjects: 52
Study: 26958015

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training for 12 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: No exercise training for 3 months
Number of subjects: 80
Study: 23939631

Group type: EXPERIMENTAL
Intervention: Sotatercept 0.1 mg/kg
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Sotatercept 0.3 mg/kg
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Sotatercept 1 mg/kg
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Sotatercept
Number of subjects: 31
Study: 21291564

Group type: EXPERIMENTAL
Intervention: Centralised and specialised outpatient intervention program consisting of combined pharmacological and psychological intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Decentralised and non-specialised standard psychiatric treatment
Number of subjects: 0
Study: 19524906

Group type: EXPERIMENTAL
Intervention: 200mg of oral iron tablets 3 times a day for 4 weeks
Number of subjects: 68
Study: 16937978

Group type: EXPERIMENTAL
Intervention: Low-intensity resistance training (LI, n = 14, 40% of 1RM)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Moderate-intensity resistance training (MI, n = 12, 60% of 1RM)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: High-intensity resistance training (HI, n = 14, 80% of 1RM)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (C, n = 10)
Number of subjects: 58
Study: 15571539

Group type: EXPERIMENTAL
Intervention: MSHO program (intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MSHO nursing home enrollees (intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control-in group (control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control-out group (control)
Number of subjects: 0
Study: 11158764

Group type: EXPERIMENTAL
Intervention: Gemifloxacin (320 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Trovafloxacin (200 mg)
Number of subjects: 12
Study: 9034243

Group type: EXPERIMENTAL
Intervention: Oleic acid rich diet
Number of subjects: 22

Group type: COMPARATOR
Intervention: Linoleic acid rich diet
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 22
Study: 8509683

Group type: EXPERIMENTAL
Intervention: diclofenac sodium 0.1% eye drops (Voltaren Ophthalmic)
Number of subjects: 50

Group type: COMPARATOR
Intervention: prednisolone acetate 1.0% eye drops (Pred Forte)
Number of subjects: 50
Study: 29092630

Group type: EXPERIMENTAL
Intervention: Lifestyle enhanced home visiting curriculum
Number of subjects: 54

Group type: COMPARATOR
Intervention: Standard home visiting curriculum (control)
Number of subjects: 54
Study: 27541556

Group type: EXPERIMENTAL
Intervention: Structured cancer survivorship care plan (SCP) transition visit
Number of subjects: 34

Group type: COMPARATOR
Intervention: SCP transition visit coupled with a coordinated follow‐up visit from the primary care provider (PCP)
Number of subjects: 34
Study: 24980063

Group type: EXPERIMENTAL
Intervention: 7-week programme (n=45)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group (n=42)
Number of subjects: 87
Study: 22264371

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia for eight days, target temperature of 35.0°C achieved by endovascular catheters.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional temperature management.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional temperature management
Number of subjects: 50
Study: 20437564

Group type: EXPERIMENTAL
Intervention: Long-interval T2-weighted subtraction (T2w-Sub) imaging
Number of subjects: 120

Group type: COMPARATOR
Intervention: Monthly gadolinium-enhanced T1-weighted (Gd-T1w) imaging
Number of subjects: 120
Study: 18672190

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glyburide
Number of subjects: 0
Study: 16165718

Group type: EXPERIMENTAL
Intervention: Oral ferrous fumarate (Neo‐fer) 120 mg orally once daily
Number of subjects: 19

Group type: COMPARATOR
Intervention: Intravenous iron sucrose (Venofer) 200 mg intravenously 3 times during a period of 14 days
Number of subjects: 19
Study: 12835216

Group type: EXPERIMENTAL
Intervention: FilterWire-Ex (FW)
Number of subjects: 53
Study: 10809863

Group type: EXPERIMENTAL
Intervention: Odorants with a sedative effect
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other odorants
Number of subjects: 0
Study: 8665383

Group type: EXPERIMENTAL
Intervention: Praziquantel 30 mg/kg
Number of subjects: 301
Study: 2005563

Group type: EXPERIMENTAL
Intervention: Combination of lidocaine, epinephrine, hyaluronidase with bupivacaine
Number of subjects: 117

Group type: COMPARATOR
Intervention: Any other combinations of lidocaine, epinephrine, and hyaluronidase with bupivacaine
Number of subjects: 117
Study: 6519165

Group type: EXPERIMENTAL
Intervention: Lasix (40 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Furix (40 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Intravenous furosemide
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Lasix and Furix
Number of subjects: 8
Study: 31118148

Group type: EXPERIMENTAL
Intervention: Ambulatory event monitoring (AEM) for 30 days post-TAVR
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Right bundle branch block (RBBB) as a risk factor
Number of subjects: 150

Group type: COMPARATOR
Intervention: Patients without incident high-grade atrioventricular block (H-AVB)
Number of subjects: 150
Study: 29458928

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (28,000 IU weekly for 8 weeks)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 27736842

Group type: EXPERIMENTAL
Intervention: Panitumumab plus best supportive care (BSC)
Number of subjects: 377

Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Panitumumab plus best supportive care (BSC) in wild-type RAS mCRC
Number of subjects: 377

Group type: COMPARATOR
Intervention: Best supportive care (BSC) in wild-type RAS mCRC
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Panitumumab in patients with RAS mutations
Number of subjects: 377
Study: 24881917

Group type: EXPERIMENTAL
Intervention: Methotrexate 1 g/m(2) over 24 hours with intrathecal injection (MTX1 arm)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Methotrexate 3 g/m(2) over 3 hours without intrathecal injection (MTX3 arm)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Overall treatment in Japan (both MTX1 and MTX3 arms)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Overall treatment in international study (both MTX1 and MTX3 arms)
Number of subjects: 44
Study: 22552038

Group type: EXPERIMENTAL
Intervention: 20 μg vitamin D3 daily for 10 weeks
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 7 μg 25-hydroxyvitamin D3 daily for 10 weeks
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 20 μg 25-hydroxyvitamin D3 daily for 10 weeks
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 20095068

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 17388752

Group type: EXPERIMENTAL
Intervention: Cyproheptadine hydrochloride (CH) 2 mg QID for 1 week followed by 4 mg QID for 11 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 15576390

Group type: EXPERIMENTAL
Intervention: rLH supplementation (150 IU) in addition to rFSH (225 IU starting dose)
Number of subjects: 260

Group type: COMPARATOR
Intervention: rFSH step-up protocol (increased by 150 IU)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Control group (normal responders with rFSH monotherapy)
Number of subjects: 260
Study: 12213688

Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 255

Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 255
Study: 9466083

Group type: EXPERIMENTAL
Intervention: Metronidazole 1 percent cream applied once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 0
Study: 8595079

Group type: EXPERIMENTAL
Intervention: Topical anaesthesia with liposomal gel formulation containing 2% tetracaine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vitro drug liberation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vivo penetration rate of tetracaine
Number of subjects: 0
Study: 1974941

Group type: EXPERIMENTAL
Intervention: Methylfolate, 15 mg daily for 6 months in addition to standard psychotropic treatment
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study: 141633

Group type: EXPERIMENTAL
Intervention: Falope-Ring banding
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 4% Xylocaine applied to the tubes during Falope-Ring banding
Number of subjects: 150

Group type: COMPARATOR
Intervention: Laparoscopic tubal fulguration
Number of subjects: 150
Study: 30617490

Group type: EXPERIMENTAL
Intervention: Gadobutrol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Gadoterate meglumine
Number of subjects: 40
Study: 30003324

Group type: EXPERIMENTAL
Intervention: Ibuprofen gel phonophoresis
Number of subjects: 61

Group type: COMPARATOR
Intervention: Ibuprofen cream phonophoresis
Number of subjects: 61
Study: 26582047

Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg at induction, followed by 0.25 mg/kg/h continuous infusion for 30 min)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (0.9% saline, 0.05 ml/kg at induction, followed by 0.025 ml/kg/h continuous infusion for 30 min)
Number of subjects: 120
Study: 25323181

Group type: EXPERIMENTAL
Intervention: Lactated Ringer's (LR) solution
Number of subjects: 78

Group type: COMPARATOR
Intervention: 4.3% dextrose in 0.18% saline (DS)
Number of subjects: 78
Study: 22997792

Group type: EXPERIMENTAL
Intervention: Acupotomy treatment once a week for 3 weeks.
Number of subjects: 180

Group type: COMPARATOR
Intervention: Electroacupuncture treatment 3 times a week for 3 weeks.
Number of subjects: 180
Study: 20332722

Group type: EXPERIMENTAL
Intervention: Conventional neuro-rehabilitation protocol (therapeutic exercise and occupational therapy) plus 60 minutes of mental practice training for 3 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional neuro-rehabilitation protocol (therapeutic exercise and occupational therapy) for 3 weeks
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Rehabilitation program plus mental practice training for 3 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional neuro-rehabilitation program for 3 weeks
Number of subjects: 36
Study: 17341751

Group type: EXPERIMENTAL
Intervention: Short form data entry strategy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Long form data entry strategy
Number of subjects: 100
Study: 16184722

Group type: EXPERIMENTAL
Intervention: Betamethasone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Diclofenac potassium
Number of subjects: 40
Study: 12452936

Group type: EXPERIMENTAL
Intervention: Pantoprazole 20 mg
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg
Number of subjects: 221

Group type: COMPARATOR
Intervention: Nizatidine 150 mg
Number of subjects: 221
Study: 10077172

Group type: EXPERIMENTAL
Intervention: Combination therapy with recombinant interferon-alpha2b (rIFN-alpha2b) and zidovudine (ZDV)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Zidovudine (ZDV) alone
Number of subjects: 256
Study: 7745037

Group type: EXPERIMENTAL
Intervention: Ascorbic acid in seminal plasma
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Urate concentrations in seminal plasma
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Luminol-chemiluminescence (CL) in washed semen
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Correlation of ascorbic acid with CL signals
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Correlation of ascorbic acid with sperm morphology
Number of subjects: 46
Study: 2285619

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 6938242

Group type: EXPERIMENTAL
Intervention: New drug combination (cincain chloride, tri‐iodomethane, tranexamic acid, propyl‐hydroxy‐benzoic acid in Gelfoam)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (sockets allowed to heal spontaneously)
Number of subjects: 15
Study: 30932783

Group type: EXPERIMENTAL
Intervention: RNI+ (patients with rapid neurological improvement)
Number of subjects: 91
Study: 28606102

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 26189808

Group type: EXPERIMENTAL
Intervention: Surgical treatment (rotator cuff repair)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Surgical treatment (rotator cuff repair) without retear
Number of subjects: 56
Study: 23484041

Group type: EXPERIMENTAL
Intervention: Interactive iPad presentation
Number of subjects: 90

Group type: COMPARATOR
Intervention: Paper consent
Number of subjects: 90
Study: 21057805

Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 1019

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy
Number of subjects: 1019

Group type: COMPARATOR
Intervention: Ranibizumab-based therapy
Number of subjects: 1019

Group type: COMPARATOR
Intervention: Low vision rehabilitation
Number of subjects: 1019

Group type: COMPARATOR
Intervention: Visual acuity
Number of subjects: 1019

Group type: COMPARATOR
Intervention: Choroidal neovascularisation
Number of subjects: 1019
Study: 19054783

Group type: EXPERIMENTAL
Intervention: 100 mg/day soy isoflavones
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 17309452

Group type: EXPERIMENTAL
Intervention: Azelaic acid applied once a day
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Adapalene
Number of subjects: 65
Study: 15539961

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg q x d)
Number of subjects: 45
Study: 10235419

Group type: EXPERIMENTAL
Intervention: Ketoprofen 25 mg
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Ketoprofen 50 mg
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Dipyrone 500 mg
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 8966143

Group type: EXPERIMENTAL
Intervention: Benazepril (10 mg once daily)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Captopril (50 mg once daily)
Number of subjects: 31
Study: 1758250

Group type: EXPERIMENTAL
Intervention: IG/IH nerve block (0.25% bupivacaine, 1 mg/kg)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl (1 microgram/kg)
Number of subjects: 75

Group type: COMPARATOR
Intervention: General anesthesia (Control)
Number of subjects: 75
Study: 7117428

Group type: EXPERIMENTAL
Intervention: Oral salbutamol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Combined oral and inhalation salbutamol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Combined therapy (oral and inhalation)
Number of subjects: 10
Study: 30659063

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT) plus asthma education
Number of subjects: 168

Group type: COMPARATOR
Intervention: Asthma education talk plus 3 telephone follow‐ups (control group)
Number of subjects: 168
Study: 28347296

Group type: EXPERIMENTAL
Intervention: Group A questionnaire pack (4 pages: demographic and EQ-5D-3L questionnaires)
Number of subjects: 18190

Group type: COMPARATOR
Intervention: Group B questionnaire pack (8 pages: HADS and PCL-C questionnaires included)
Number of subjects: 18190

Group type: EXPERIMENTAL
Intervention: Group A (EQ-5D-3L mobility domain)
Number of subjects: 18190

Group type: COMPARATOR
Intervention: Group B (EQ-5D-3L mobility domain)
Number of subjects: 18190

Group type: EXPERIMENTAL
Intervention: Group A (anxiety/depression domain)
Number of subjects: 18190

Group type: COMPARATOR
Intervention: Group B (anxiety/depression domain)
Number of subjects: 18190
Study: 25181946

Group type: EXPERIMENTAL
Intervention: 60 mg prednisolone per day, tapered to 5 mg over 8 weeks
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: 10 mg prednisolone per day, tapered to 5 mg over 8 weeks
Number of subjects: 450

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: 60 mg prednisolone per day
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: 10 mg prednisolone per day
Number of subjects: 450
Study: 22909076

Group type: EXPERIMENTAL
Intervention: self‐administered relaxation acupressure
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: self‐administered stimulating acupressure
Number of subjects: 375

Group type: COMPARATOR
Intervention: standard of care
Number of subjects: 375